Romain Capoulade Inserm DR Grand Ouest

Dr. Romain Capoulade Inserm DR Grand Ouest

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2013 in JACC
Verified
Journal Article
Closed access
MCMarie-Annick Clavel
Marie-Annick Clavel
DMDavid Messika-Zeitoun
David Messika-Zeitoun
PPPhilippe Pibarot
Philippe Pibarot
SAShivani R. Aggarwal
Shivani R. Aggarwal
JMJoseph Malouf
Joseph Malouf
MEMaurice Enriquez-Sarano
Maurice Enriquez-Sarano

1 September 2014 in JACC
Verified
Journal Article
Closed access
MCMarie-Annick Clavel
Marie-Annick Clavel
PPPhilippe Pibarot
Philippe Pibarot
DMDavid Messika-Zeitoun
David Messika-Zeitoun
RORomain Capoulade Inserm DR Grand Ouest
Romain Capoulade Inserm DR Grand Ouest
JMJoseph Malouf
Joseph Malouf
MEMaurice Enriquez-Sarano
Maurice Enriquez-Sarano

1 September 2015 in JACC
Verified
Journal Article
Closed access
RORomain Capoulade Inserm DR Grand Ouest
Romain Capoulade Inserm DR Grand Ouest
KCKwan L. Chan
Kwan L. Chan
CYCalvin Yeang
Calvin Yeang
PMPatrick Mathieu
Patrick Mathieu
YBYohan Bossé
Yohan Bossé
STSotirios Tsimikas
Sotirios Tsimikas

1 October 2012 in JACC
Verified
Journal Article
Closed access
MCMarie-Annick Clavel
Marie-Annick Clavel
JDJean G. Dumesnil
Jean G. Dumesnil
RORomain Capoulade Inserm DR Grand Ouest
Romain Capoulade Inserm DR Grand Ouest
PMPatrick Mathieu
Patrick Mathieu
MSMario Sénéchal
Mario Sénéchal
PPPhilippe Pibarot
Philippe Pibarot

1 July 2019 in JACC
Verified
Journal Article
Closed access
LTLionel Tastet
Lionel Tastet
CTChristophe Tribouilloy
Christophe Tribouilloy
SMSylvestre Maréchaux
Sylvestre Maréchaux
EVE. Mara Vollema
E. Mara Vollema
VDVictoria Delgado
Victoria Delgado
PPPhilippe Pibarot
Philippe Pibarot

1 November 2018 in JAMA Cardiology
Verified
Journal Article
Closed access
PDF file
PLPatrizio Lancellotti
Patrizio Lancellotti
JMJulien Magne
Julien Magne
RDRaluca Dulgheru
Raluca Dulgheru
MCMarie-Annick Clavel
Marie-Annick Clavel
EDErwan Donal
Erwan Donal
COCécile Oury
Cécile Oury
In the western world, calcific aortic stenosis (AS), the most common valvular heart disease, represents a major public health burden.1 Currently, there is no pharmacological treatment that prevents or slows the progression of AS.2 Surgical aortic valve replacement (SAVR) and transcatheter aortic valve replacement (TAVR) are the only therapies to significantly improve both survival and symptoms3,4 and are recommended in symptomatic patients with severe AS.5,6 Quiz Ref ID The management of patients with asymptomatic severe AS, particularly the choice between early intervention vs watchful waiting, continues to be a matter of debate.7,8 Current guidelines advocate delaying AVR until symptoms or left ventricular (LV) systolic dysfunction develop.5,6 However, observational studies in 20109 and 201510 have suggested that early elective AVR might improve outcomes in patients with severe asymptomatic AS. This approach has been reinforced by continued advances in surgical techniques and aortic valve prostheses, the advent of TAVR, and the low perioperative mortality and morbidity rates achieved in valve centers of reference.11,12 However, preemptive surgery before onset of symptoms or LV systolic dysfunction is considered in only a selected group of patients after careful risk stratification. This is at least in part because the evidence for intervention in asymptomatic severe AS is derived from small, heterogeneous, retrospective, single-center studies, which have generally included the need for AVR (not always motivated by the development of symptoms or LV dysfunction) in the composite study end point.13-20 Moreover, decision making for AVR remains particularly difficult in older patients in whom it is sometimes unclear if the benefits of intervention outweigh the risk.5,6